相关实验视频
Updated: Jul 22, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
血小板糖蛋白IIb/IIIa受体对手在心血管疾病中的作用
D A Vorchheimer1, J J Badimon, V Fuster
1Department of Medicine, Mount Sinai School of Medicine and the Zena and Michael A. Weiner Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029-6574, USA.
血小板糖蛋白 (GP) IIb/IIIa受体对抗剂有效地减少急性冠状动脉综合征中的心脏事件,特别是在皮肤再血管化过程中. 对于针对慢性对抗性的口服药物,需要进一步的研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血栓形成的原因之一是血栓形成.
背景情况:
- 动脉硬性斑块破裂引发了血栓形成,这是急性冠状动脉事件的主要原因.
- 血小板抑制剂对于治疗急性冠状动脉综合征至关重要.
- 糖蛋白 (GP) IIb/IIIa受体是血小板聚合的核心.
研究的目的:
- 审查血小板激活和聚合机制.
- 研究GP IIb/IIIa受体在急性冠状动脉综合征中的作用.
- 总结GP IIb/IIIa受体对抗剂的临床试验.
主要方法:
- 搜索了MEDLINE和主要的心脏病会议摘要 (1993-1998).
- 包括静脉注射GP IIb/IIIa对抗剂的随机,安慰剂控制试验 (>500名受试者).
- 根据出版地点评估数据质量.
主要成果:
- GP IIb/IIIa受体对抗剂在皮肤再血管化中显著减少死亡或心肌梗塞 (OR 0.42-0.84).
- 对急性冠状动脉综合征 (OR 0.70-0.89) 的好处更为适度.
- 口服GP IIb/IIIa对抗剂在慢性使用中的有效性仍未得到充分研究.
结论:
- 静脉注射的GP IIb/IIIa对抗剂在急性冠状动脉综合征和皮肤间干预中有效.
- 这些药物代表了减少血栓事件的关键治疗策略.
- 口服GPIIb/IIIa抗剂的疗效需要进一步研究.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care

